Why the study?
Identifying the offending drug in patients receiving multiple chemotherapy agents is challenging, requiring differentiation between kinase inhibitor-induced hand foot skin reaction and conventional chemotherapy-induced hand foot syndrome.
Clinical morphology of early skin reactions can help differentiate small-molecule kinase inhibitor-induced hand foot skin reaction from conventional chemotherapy-induced hand foot syndrome.
Answers are grounded in this paper and cite their sources.
Challenges identifying culprit agents in toxic erythema persist with FLT3 inhibitors; leaves open systematic characterization in pediatric oncology.
Various chemotherapy-induced reaction patterns are described; collectively called ‘toxic erythema of chemotherapy’. Although temporal association of chemotherapeutic agent in a patient with cancer makes the diagnosis easy, especially when they present with an acute eruption; identification of the offending agent when they are receiving a concoction of chemotherapeutic agents makes it challenging. With the advent of newer agents like small-molecule FLT3 kinase inhibitors, reaction secondary to these agents (hand foot skin reaction) must be differentiated from the conventional chemotherapeutic agent induced reactions (hand foot syndrome). We hereby present a case of sorafenib-induced hand foot skin reaction and highlight how morphology of the early skin reaction was adequate in differentiating it from hand foot syndrome.
No takes yet. Share an insight, caveat, or question.
Hegde et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: